Navigation Links
Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
Date:8/16/2012

THE WOODLANDS, Texas, Aug. 16, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today reported preliminary results from Phase 1 studies of LX2931 and LX7101.

The Phase 1 study of LX2931, an inhibitor of sphingosine-1-phosphate lyase, was a dose-ranging study to explore higher doses of LX2931 in patients with rheumatoid arthritis. The study involved 10 patients with rheumatoid arthritis, eight of whom were randomized to LX2931 and two to placebo.  The primary endpoint in the study was an evaluation of the safety and tolerability of escalating doses of LX2931 compared with placebo over 12 weeks in subjects with active rheumatoid arthritis.  Secondary endpoints included pharmacokinetic and disease activity measures. 

Patients in the study received increasing doses over the course of the study, beginning at 50 mg QD and escalating to 500 mg QD.  LX2931 was well-tolerated at all doses evaluated, with no serious adverse events and no withdrawals due to adverse events. Seven of eight patients on LX2931 achieved drug trough levels greater than 60 ng/ml, a pharmacokinetic measure which a post-hoc analysis of data from a prior Phase 2 study of LX2931 had suggested was associated with better responses in American College of Rheumatology (ACR) measures in the study.  Six of the eight LX2931-treated patients experienced a drop from baseline in the DAS28 score of greater than or equal to 1.2, as did both placebo patients.  ACR20 and ACR50 responses were achieved at varying frequencies in both LX2931-treated and placebo patients, but two of eight patients dosed with LX2931 achieved an ACR70 response during the course of the study,
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
2. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
3. Lexicon to Provide Second Quarter 2012 Financial Results
4. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
5. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
6. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
7. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
8. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
9. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
10. Lexicon to Provide First Quarter 2012 Financial Results
11. Nouveau Life Pharmaceuticals (NOUV) Releases Calcium & Vitamin D for Strong Bones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Ranibizumab Market, 2012-2019" ... ranibizumab was approved by CFDA to treat wet age- ... a product of Novartis, is available in the Chinese ... developed drug for the treatment of wet AMD in ...
(Date:8/28/2015)... Company plc ("Perrigo") (NYSE: PRGO ; TASE) today ... OTC brands from GSK in an all cash transaction ... demonstration of Perrigo,s unique ability to maximize brand value ... countries.  Perrigo Chairman, President and CEO ... to complete this transaction, which clearly demonstrates our ability ...
(Date:8/28/2015)... PUNE, India , August 28, 2015 ... Essential Oils), Livestock (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by ... , Asia-Pacific , and Rest of ... by MarketsandMarkets, The global market for Eubiotics was valued at ... USD 7.05 Billion by 2020, at a CAGR of 7.4% ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
... - Partnership aims to provide convenient access to vaccination ... at work, - "Let,s Fight Flu Together!" initiative ... to 18 years old(1), - Campaign goal is ... for those vaccinated, CAMBRIDGE, Mass., Nov. 10 ...
... Well-Tolerated, Significantly Inhibited ... November 10 at 8:30 ... a.m. ET-, NEW ... a biotechnology company focused on,the development of compounds for the treatment of cardiovascular ...
Cached Medicine Technology:Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families 'Let's Fight Flu Together!' 2Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families 'Let's Fight Flu Together!' 3Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families 'Let's Fight Flu Together!' 4Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families 'Let's Fight Flu Together!' 5Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families 'Let's Fight Flu Together!' 6VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 2VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 3VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 4VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 5VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 6VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 7VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 8
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health Sciences ... sell Arterosil and Arterosil HP, and that all claims and counterclaims have been ... Sciences, LLC (VHS) in the United States District Court for the Southern District ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... The Kentucky ... workers are qualified for the position they are applying for, they are unable to ... many employers are considering altering drug testing policies in order to be able to ...
(Date:8/28/2015)... , ... August 28, 2015 , ... As reported ... Merz, received FDA clearance for results that last for two years, the longest ... news for patients who are looking for a long-lasting, effective solution for their cellulite, ...
(Date:8/28/2015)... ... , ... “ Frequentz ” was featured on NewsWatch as part of its ... market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology ... to track product movement from beginning to end. , Businesses benefit greatly from having ...
(Date:8/28/2015)... Jordan, Utah (PRWEB) , ... August 28, 2015 ... ... been awarded a three-year accreditation for its adolescent residential, counseling, day treatment and ... demonstrates that it meets international standards for quality and its pursuit of excellence. ...
Breaking Medicine News(10 mins):Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2
... MedQuist Inc.,(Pink Sheets: MEDQ) announces that it ... Chain Systems, one of the nation,s largest ... and,allowing them to complete the MedQuist suite ... solutions. As partners, MedAssets and MedQuist ...
... 2 Filtrona Fibertec, a division of,Filtrona plc, ... fluid handling components, celebrated the completion,of the recent ... a Grand Opening,celebration. (Logo: http://www.newscom.com/cgi-bin/prnh/20061127/DCM011LOGO ... more than double the size of,production floor space ...
... Oct. 2 Abbott (NYSE: ABT ),announced today ... waived status under the Clinical Laboratory Improvement Amendements,of 1988 ... it,more widely available for use beyond the hospital setting. ... and accurate and,can be made more broadly available to ...
... California, October 2 joimax GmbH, Campbell,CA, is pleased ... Inc. the company is moving to larger premises in ... October 1st, 2007,joimax, Inc. will be located at ... CA 95008 USA "This move reflects the strong ...
... Genetic Engineering and,Biotechnology News, (GEN) first online video ... up by more than 180 media outlets since its,release ... to run on GEN,s,Biotech Video Channel, is a corporate ... the Multimedia News Release, go to:, http://www.prnewswire.com/mnr/gen/29564/ ...
... has added over,6,000 menu items from 70 of ... http://www.NutritionPedia.com, the only online nutrition,search engine. ... content of their favorite menu items available at ... style restaurants such as,Applebee,s Neighborhood Bar and Grill, ...
Cached Medicine News:Health News:MedQuist and MedAssets Sign Multi-Year Contract for Clinical Documentation Workflow Solutions 2Health News:MedQuist and MedAssets Sign Multi-Year Contract for Clinical Documentation Workflow Solutions 3Health News:Filtrona Fibertec Ningbo, China Plant Celebrates Expansion 2Health News:Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge 2Health News:Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge 3Health News:Video: GEN Video Hits Home with Web Audience 2Health News:NutritionPedia Adds Nutrition Facts for Over 6,000 Menu Items From 70 Leading Fast-Casual and Family Dining Restaurant Chains 2
Inquire...
Inquire...
... and optical performance, the SZX7 is designed ... in every task, from routine preparations to ... the best zoom ratios in its class ... color and accurate reproduction of the original ...
... The series SV stereomicroscopes are ... Thanks to their mature modular ... the job in hand. This ... of demanding routine applications will ...
Medicine Products: